Changzhou Huasheng Pharmaceutical Co. Ltd.

Main objectives: 1. To study the pharmacokinetic behavior of the test formulation of fluoxetine hydrochloride capsules (20 mg/pill, Changzhou Watson Pharmaceuticals Co., Ltd.) and the reference formulation of fluoxetine hydrochloride capsules (20 mg/pill, licensee: LILLY FRANCE) in healthy Chinese subjects after a single oral administration on an empty stomach, and to evaluate the bioequivalence of the two formulations after oral administration on an empty stomach. 2. To study the pharmacokinetic behavior of the test formulation of fluoxetine hydrochloride capsules (20 mg/pill, Changzhou Watson Pharmaceuticals Co., Ltd.) and the reference formulation of fluoxetine hydrochloride capsules (20 mg/pill, licensee: LILLY FRANCE) in healthy Chinese subjects after a single oral administration on a empty stomach, and to evaluate the bioequivalence of the two formulations after oral administration on a empty stomach. Secondary objectives: To evaluate the safety of the test formulation and the reference formulation of fluoxetine hydrochloride capsules in healthy Chinese subjects after a single oral administration on an empty stomach.

Primary objective: Using olanzapine tablets (Zyprexa, 5 mg) produced by Eli Lilly and Company as the reference preparation and olanzapine tablets (Ximin, 5 mg) produced by Changzhou Watson Pharmaceuticals Co., Ltd. as the test preparation, a single-center, randomized, open, two-period, double-crossover clinical trial design was conducted to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary objective: To evaluate the safety of the test preparation and the reference preparation in healthy Chinese subjects.